FDA 483 - Samsung Biologics Co., Ltd. - July 25, 2017
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Samsung BioLogics' drug substance manufacturing facility in Yeonsu-gu, Incheon, Korea, revealed significant deficiencies in laboratory controls, deviation investigations, and microbial control. The firm failed to adequately verify test methods, properly investigate deviations, ensure microbial control procedures, and conform to USP-NF standards for critical raw materials. These issues indicate a lack of scientifically sound and appropriate procedures to assure product quality and purity.
ID · c6c8d9be-3460-4955-aebd-c5d47eea5727